Company intelligence / Profile preview

DPASS SUD

Perth, Western Australia, Australiaprovince-sud.nc ↗

Ownership: Private
Development stage: Other

Overview

SUDA Pharmaceuticals develops and commercializes oro-mucosal drug delivery systems. Its lead product ZolpiMist™ is approved by the TGA and marketed in the USA for short-term insomnia. Other programs include early-stage development of oral sprays for migraine, motion sickness, epilepsy, and oncology indications. The company has demonstrated improved uptake and reduced side effects with its platform compared to traditional formulations.

Therapeutic areas: OncologyPsychiatryNeurology
Modalities: Small moleculeOral spray drug delivery
Industry: Biotech

Partnerships

MedPharm (drug formulation partner)

Beyond the preview

Go deeper on DPASS SUD.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DPASS SUD.

Explore the full profile